The POC Worked. Now What?

Your AI pilot ran well. The model summarized clinical documents accurately. The agent navigated your internal data sources and returned answers that impressed the steering committee. Somebody put together a slide deck. Leadership signed off on "moving to the next phase."

Then the questions started. Who validates this? What happens when it gives a wrong answer during a trial? Can we show the FDA what the agent did and why? Does this touch PHI? Which system of record owns the output?

This is where most life sciences AI projects stall. Not because the technology failed. Because the gap between a controlled demo and a compliant production system is larger than it looks from the outside, and almost nobody talks honestly about what fills that gap.

This post is about that gap.

Why Life Sciences Is a Different Category of Hard

Every enterprise AI deployment has friction. Life sciences has friction plus a regulatory surface area that most AI teams have never encountered before.

Consider what a production AI agent might touch in a mid-size biotech or CRO: clinical trial data under 21 CFR Part 11, manufacturing batch records under GMP, adverse event documentation under FDA pharmacovigilance guidelines, medical writing workflows adjacent to IND and NDA submissions. The moment an AI agent interacts with any of those systems, it becomes a computerized system under GxP. And computerized systems under GxP require validation.

Validation is not testing. Testing checks whether something works. Validation is the documented proof that the system consistently performs its intended function within defined parameters, across time, with a traceable audit trail. The FDA's guidance on computer system validation has been around since 2003, and the principles have not changed because you are using a language model instead of a database query.

AWS published a useful technical reference on building AI agents in GxP environments that is worth reading in full. The core tension they identify is real: traditional validation approaches assume deterministic software behavior, and LLM-based agents are probabilistic by design. That is not an unsolvable problem, but it requires deliberate architectural choices that most POC builds never make.

Four Specific Things That Break Between POC and Production

1. The agent has no audit trail

Your POC probably logged inputs and outputs. Production requires more than that. In a regulated workflow, you need to know not just what the agent returned, but what reasoning path it took, which tools it called, in what order, with what parameters, and what it would have done differently if the inputs had changed slightly. That is not a logging problem. It is an architecture problem.

Agents built on top of general-purpose frameworks often treat reasoning as a black box by default. Getting a GxP-defensible audit trail out of an LLM-driven agent requires explicit instrumentation from day one, including structured logging of tool calls, intermediate states, confidence signals, and fallback behaviors. Retrofitting this onto a POC architecture is technically possible, but it usually means rebuilding the core orchestration layer.

2. The data governance model is wrong

Most POCs connect to a curated sample of clean internal data. Production connects to the actual systems. In a life sciences company of any size, that means navigating a mosaic of data sources with different sensitivity classifications, access control schemes, and retention policies. PHI has HIPAA implications. Trial data has Part 11 implications. Manufacturing data may have GMP audit implications.

An agent that retrieves data across those boundaries needs explicit data governance controls baked into the retrieval layer: role-based access that mirrors existing entitlements, data lineage tracking, clear rules about what can be cached and what must be retrieved fresh. These requirements are well-documented in frameworks like HHS HIPAA Security guidance and FDA's Part 11, but translating them into agent architecture is a design conversation that POCs rarely have.

3. Model behavior is not stable

The model you used in your pilot may not be the model you run in production six months later. Foundation model providers update, fine-tune, and deprecate model versions. For a consumer application, a slight shift in output style is acceptable. For a regulated workflow where the agent is participating in clinical data review or regulatory document generation, model drift is a validation event. It triggers revalidation of the system.

This has real cost and schedule implications. Life sciences engineering teams that have not thought through model versioning, change control procedures, and re-validation triggers will discover this problem at the worst possible moment, usually right before a submission deadline.

4. Human-in-the-loop is more than a UI element

Reviewers in regulated workflows are not just users. They are accountable parties. Under FDA guidelines, a reviewer who approves an AI-generated output is taking professional and regulatory responsibility for that output. That changes the design requirements for human oversight significantly.

A checkbox saying "reviewed and approved" is not sufficient. The interface needs to show what the agent did, provide enough context for a genuine expert review (not just rubber-stamping), preserve the reviewer's identity and timestamp with non-repudiation, and feed that review decision back into the audit trail. Most POC UIs are not built to these standards. Building them properly takes more time than most engineering estimates account for.

What Validation Actually Looks Like for AI Agents

The FDA's General Principles of Software Validation guidance provides the foundational framework. Applied to AI agents, a reasonable validation approach looks something like this:

First, define the intended use precisely. Not "assist with clinical data review" but a specific, bounded description of what the agent does, what inputs it accepts, what outputs it produces, and what it is explicitly not designed to do. Vague intended use statements are the most common validation gap we see.

Second, establish acceptance criteria before you build. What does acceptable performance look like? For a document summarization agent, that might mean 95% accuracy on a defined test set of representative documents, with explicit failure modes documented. For a regulatory intelligence agent, it might mean recall rates for specific document classes. The criteria need to be agreed upon by the business owner, the quality team, and whoever will be accountable for the output.

Third, run IQ/OQ/PQ protocols adapted for probabilistic systems. Installation qualification checks that the infrastructure is correct. Operational qualification tests that the system performs its intended function on representative inputs. Performance qualification runs the system in a production-equivalent environment. Each phase produces documented evidence. The evidence is what goes in the validation package.

Fourth, establish ongoing monitoring and change control. Validation is not a one-time event. Any change to the model, the retrieval layer, the tool set, or the system prompts is a change event that needs to be assessed for its impact on the validated state. Some changes are minor and require only documentation. Others require partial or full revalidation.

This is not exotic. It is standard software validation practice adapted for a new category of software behavior. The adaptation is the hard part, and it requires people who understand both GxP quality systems and modern AI architecture. That combination is genuinely rare.

The Org Structure Problem Nobody Mentions

Even when the technical architecture is sound and the validation approach is defensible, life sciences AI projects hit a wall that is purely organizational.

The IT team owns the infrastructure. The quality team owns validation. The clinical or regulatory function owns the workflow. The data science team built the model. Legal and compliance have concerns about liability. Each of these groups has veto power over some aspect of the deployment, and they are not used to coordinating on AI systems because they have never had to before.

McKinsey's research on agentic AI in life sciences frames this as an enterprise operating model problem, which is accurate. The technical work is actually the easier half. The governance structure that decides who approves an AI system for use in a regulated workflow, who owns revalidation when the model changes, and who is accountable when it produces an error — that structure does not exist yet in most organizations, and building it takes longer than building the agent.

Where to Actually Start (and What to Avoid)

Given all of this, the question becomes: what is a defensible starting point for a life sciences team that wants to deploy AI agents in production, not just run pilots?

Start with workflows that are high-value but not directly in the critical path of a regulated submission. Medical literature monitoring, internal document search, adverse event signal detection for flagging (not for final determination), meeting summarization, protocol deviation trend analysis. These are areas where AI can deliver real productivity gains without sitting directly in the 21 CFR Part 11 chain. They let your organization build the governance muscle and technical infrastructure before you need to validate a mission-critical system.

Avoid building your first production system directly on top of a general-purpose chat interface or no-code agent platform. Those tools are excellent for exploration. They are not built for the instrumentation, audit trail, and change control requirements of a regulated environment. The gap between what they provide and what GxP demands is wide enough that you will spend more time working around the tool than using it.

Invest in data readiness before agent capability. The highest-leverage investment most life sciences AI teams can make is not a better model. It is cleaner, better-governed data with documented lineage. An agent built on top of well-structured, access-controlled data is dramatically easier to validate and more reliable in production than a more sophisticated agent operating on a data swamp.

Get quality involved at architecture review, not at deployment sign-off. The most expensive validation surprises are the ones discovered after the system is built. Quality teams are not blockers; they are the people who know what the FDA will ask when they inspect your electronic records. Involving them in the design phase costs days. Involving them after the fact costs months.

The Honest Timeline

For a first production AI agent in a regulated life sciences workflow, a team that knows what it is doing should budget six to nine months from requirements sign-off to validated production deployment. Faster is possible for lower-risk workflows. Longer is common for anything touching submission-critical data.

Most POC timelines are four to eight weeks. The delta between eight weeks and nine months is not engineering work. It is validation documentation, stakeholder alignment, quality system integration, change control procedures, and the organizational process of building something new into a compliance framework that was not designed for it.

None of that is a reason not to do it. The productivity and quality gains from well-deployed AI agents in clinical operations, regulatory affairs, and pharmacovigilance are real and substantial. Deloitte's work tracking AI adoption across the life sciences sector shows that the organizations pulling ahead are not the ones with the most advanced models. They are the ones that figured out the governance and validation piece first.

The POC got you proof of concept. Getting to proof of compliance is the actual work.

If you are working through this transition and want a realistic read on your architecture from a team that has shipped regulated AI systems in production, we are happy to compare notes.